Recombinant Fusion Proteins

"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.

Descriptor ID	D011993
MeSH Number(s)	D12.776.828.300
Concept/Terms	Recombinant Fusion Proteins Recombinant Fusion Proteins Proteins, Recombinant Fusion Fusion Proteins, Recombinant Hybrid Proteins, Recombinant Hybrid Proteins, Recombinant Proteins, Recombinant Hybrid Recombinant Hybrid Proteins Chimeric Proteins, Recombinant Chimeric Proteins, Recombinant Proteins, Recombinant Chimeric Recombinant Chimeric Proteins

Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Recombinant Proteins [D12.776.828]
Recombinant Fusion Proteins [D12.776.828.300]

Below are MeSH descriptors whose meaning is related to "Recombinant Fusion Proteins".

Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".

Recombinant Fusion Proteins
CD4 Immunoadhesins
Transcription Activator-Like Effector Nucleases
Zinc Finger Nucleases

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.

Bar chart showing 288 publications over 30 distinct years, with a maximum of 20 publications in 2004

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	1	5	6
1994	1	8	9
1995	1	5	6
1996	0	12	12
1997	1	8	9
1998	1	12	13
1999	2	10	12
2000	0	16	16
2001	1	17	18
2002	2	17	19
2003	2	11	13
2004	4	16	20
2005	1	12	13
2006	3	5	8
2007	0	7	7
2008	5	8	13
2009	2	8	10
2010	5	9	14
2011	0	8	8
2012	4	6	10
2013	2	4	6
2014	4	8	12
2015	3	5	8
2016	2	0	2
2017	0	6	6
2018	1	3	4
2019	2	0	2
2020	1	2	3
2021	2	4	6
2022	1	2	3

Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.

Rubinstein MP, Williams C, Mart C, Beall J, MacPherson L, Azar J, Swiderska-Syn M, Manca P, Gibney BC, Robinson MD, Krieg C, Hill EG, Taha SA, Rock AD, Lee JH, Soon-Shiong P, Wrangle J. Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers. J Immunol. 2022 03 15; 208(6):1362-1370.

View in: PubMed
Guo Z, Chen J, Zeng Y, Wang Z, Yao M, Tomlinson S, Chen B, Yuan G, He S. Complement Inhibition Alleviates Cholestatic Liver Injury Through Mediating Macrophage Infiltration and Function in Mice. Front Immunol. 2021; 12:785287.

View in: PubMed
Dascalu AM, Rizzo M, Rizvi AA, Stoian AP, Iancu RC, Stana D, Tudosie MS, Serban D. Safety and Outcomes of Intravitreal Aflibercept in Diabetic Macular Edema - A Systematic Review. Curr Pharm Des. 2022; 28(21):1758-1768.

View in: PubMed
Lei B, Sleiman MM, Cheng Q, Tu Z, Zhu P, Goddard M, Martins PN, Langerude L, Nadig S, Tomlinson S, Atkinson C. In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.

View in: PubMed
Toutonji A, Mandava M, Guglietta S, Tomlinson S. Chronic complement dysregulation drives neuroinflammation after traumatic brain injury: a transcriptomic study. Acta Neuropathol Commun. 2021 07 19; 9(1):126.

View in: PubMed
Ding H, Buzzard GW, Huang S, Sehorn MG, Marcus RK, Wei Y. MICA-G129R: A bifunctional fusion protein increases PRLR-positive breast cancer cell death in co-culture with natural killer cells. PLoS One. 2021; 16(6):e0252662.

View in: PubMed
Annamalai B, Parsons N, Nicholson C, Joseph K, Coughlin B, Yang X, Jones BW, Tomlinson S, Rohrer B. Natural immunoglobulin M-based delivery of a complement alternative pathway inhibitor in mouse models of retinal degeneration. Exp Eye Res. 2021 06; 207:108583.

View in: PubMed
Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA. Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clin Cancer Res. 2021 06 15; 27(12):3339-3350.

View in: PubMed
Basak S, Sakia N, Dougherty L, Guo Z, Wu F, Mindlin F, Lary JW, Cole JL, Ding F, Bowen ME. Probing Interdomain Linkers and Protein Supertertiary Structure In Vitro and in Live Cells with Fluorescent Protein Resonance Energy Transfer. J Mol Biol. 2021 03 05; 433(5):166793.

View in: PubMed
Banda NK, Tomlinson S, Scheinman RI, Ho N, Ramirez JR, Mehta G, Wang G, Vu VP, Simberg D, Kulik L, Holers VM. C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice. Front Immunol. 2020; 11:575154.

View in: PubMed

People

Explore

Similar Concepts

Top Journals